KC
MRTX

Kellner Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Kellner Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$2.43M Buy
+41,400
New +$2.33M 4.38% 8

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Kellner Capital's MRTX Position: Q4 2023 in Review

Kellner Capital opened a new position in Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023: 41,400 shares worth $2.43M. The stake represents 4.38% of the portfolio and ranks #8 among its holdings.

217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Kellner Capital held 41,400 shares of Mirati Therapeutics, Inc. Common Stock worth $2.43M as of Q4 2023.
  • Mirati Therapeutics, Inc. Common Stock was a new Kellner Capital position in Q4 2023.
  • Mirati Therapeutics, Inc. Common Stock made up 4.38% of Kellner Capital's portfolio in Q4 2023, its #8 holding.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Kellner Capital's 13F filing for Q4 2023, filed 7 Feb 2024.